TRIUMEQ (dolutegravir/abacavir/lamivudine) Patient Assistance Program
Don’t let the high cost of brand single-tablet HIV regimens disrupt your treatment. We help eligible patients access Triumeq (dolutegravir/abacavir/lamivudine) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Triumeq (dolutegravir/abacavir/lamivudine, DTG/ABC/3TC) is a once-daily, single-tablet, complete HIV-1 regimen FDA-approved for adults and pediatric patients (≥10 kg). It is also available as Triumeq PD (pediatric dispersible) for younger pediatric patients.
- Without assistance, Triumeq costs commonly run approximately $3,200–$3,700 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Triumeq for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- HLA-B*5701 testing is REQUIRED before starting Triumeq — abacavir can cause severe, life-threatening hypersensitivity in HLA-B*5701-positive patients. There is no generic Triumeq in the U.S. as of 2026. Generic abacavir/lamivudine is available, and dolutegravir is available separately.
What Is Triumeq Prescription Assistance Program?
The Triumeq Prescription Assistance Program is a manufacturer-sponsored initiative that provides Triumeq at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for HIV treatment patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, HIV provider coordination, HLA-B*5701 testing documentation, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, Triumeq costs roughly $3,200–$3,700/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$3,600.00 | Save ~$3,530/mo |
| CVS Pharmacy | ~$3,700.00 | Save ~$3,630/mo |
| Walmart | ~$3,300.00 | Save ~$3,230/mo |
| Costco | ~$3,250.00 | Save ~$3,180/mo |
Kroger | ~$3,300.00 | Save ~$3,230/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Triumeq Prescription Program?
The Patient Assistance Program is free to apply for and provides Triumeq at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Triumeq:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $3,200–$3,700 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Triumeq assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Triumeq Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Triumeq:
Triumeq (DTG/ABC/3TC) is a once-daily, single-tablet, complete HIV-1 regimen combining the integrase strand transfer inhibitor (INSTI) dolutegravir with the NRTI backbone of abacavir and lamivudine. HIV guidelines recommend INSTI-based regimens as first-line therapy for treatment-naïve patients.
How Triumeq Works:
HIV-1 replication relies on reverse transcriptase to convert viral RNA into DNA and integrase to splice it into the host genome, which combination therapy attacks at multiple steps. Triumeq combines three agents into a single tablet: dolutegravir blocks the integration of viral DNA, while abacavir and lamivudine terminate the elongation of the viral DNA chain. Because dolutegravir possesses a high genetic barrier to resistance, the virus must undergo multiple mutations to become resistant. This specific characteristic makes the entire medication regimen uniquely forgiving of occasional missed doses.
Form and use:
Triumeq is administered orally as a single tablet taken once daily, and it can be consumed with or without food. Before a patient can start this medication, mandatory HLA-B*5701 genetic testing must be performed. This screening is vital because the abacavir component in the tablet causes severe, potentially fatal hypersensitivity reactions in patients who test positive for this marker. The prevalence of this genetic marker ranges from roughly 5% to 8% depending on the patient’s ethnicity.
Generic availability:
As of 2026, there is no generic version of the single-tablet regimen Triumeq available in the United States. However, its individual components can be found separately, as generic abacavir/lamivudine forms the dual-drug backbone and dolutegravir is sold on its own as Tivicay. While medical guidelines widely recommend these integrase-inhibitor-based regimens as first-line therapies, alternative single-tablet options exist. These include competing brand-name formulations such as Biktarvy, Genvoya, Symtuza, and the two-drug regimen Dovato.
Warnings:
Triumeq carries a Boxed Warning regarding severe, sometimes fatal abacavir hypersensitivity reactions in HLA-B*5701-positive individuals, and the drug must never be restarted if a reaction is suspected. It also carries a Boxed Warning for severe, acute hepatitis B exacerbations if the medication is abruptly stopped in patients co-infected with HBV. Additional warnings involve risks of liver toxicity, rare instances of depression or suicidality, and immune reconstitution syndrome. Finally, clinical literature continues to debate a potential increased risk of cardiovascular events associated with abacavir.
FAQ (Frequently Asked Questions)
How Much Does Triumeq Cost Without Insurance?
Triumeq costs approximately $3,200–$3,700 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Triumeq at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Why Do I Need HLA-B*5701 Testing Before Triumeq?
Abacavir (a component of Triumeq) causes severe, sometimes fatal hypersensitivity reactions in patients who carry the HLA-B*5701 allele (roughly 5–8% of the population, more common in some ethnic groups). HLA-B*5701 testing is required before starting Triumeq. HLA-B*5701-positive patients should NEVER receive abacavir.
How Is Triumeq Different From Biktarvy?
Both are once-daily, single-tablet, complete INSTI-based HIV regimens. Triumeq contains dolutegravir + abacavir + lamivudine; Biktarvy contains bictegravir + emtricitabine + tenofovir alafenamide (TAF). Both have high resistance barriers and are first-line options. The choice depends on HLA-B*5701 status (Triumeq requires negative result), kidney function, hepatitis B co-infection (Biktarvy provides better HBV coverage), and tolerability.
What Should I Watch For After Starting Triumeq?
Watch for symptoms of abacavir hypersensitivity — typically appearing within the first 6 weeks: fever, rash, GI symptoms (nausea, vomiting, diarrhea, abdominal pain), constitutional symptoms (fatigue, malaise), and respiratory symptoms (cough, shortness of breath). If hypersensitivity is suspected, stop Triumeq immediately and contact your provider — never restart abacavir.
Can I Get Triumeq Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. State ADAP programs may also coordinate with Medicare for HIV-treatment patients.
What If I Have Hepatitis B Co-infection?
Tell your prescriber. Triumeq’s lamivudine has activity against HBV, but lamivudine monotherapy can lead to HBV resistance. Patients with HIV/HBV co-infection typically need a regimen that includes two HBV-active drugs — Biktarvy or a tenofovir-based regimen is usually preferred. If Triumeq is used in HBV co-infection, additional HBV-active therapy may be needed.
What If My Application Is Denied?
If denied, we explore alternatives — switching to another INSTI-based regimen with its own PAP (Biktarvy, Dovato, Genvoya), state ADAP, the manufacturer’s copay program for commercially insured patients, or independent foundations. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Triumeq, our team may be able to help you access assistance programs designed to make brand single-tablet HIV regimens affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.